Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dong-A PharmTech has said that that its European licensee, Falk Pharma, has initiated a Phase II proof of concept clinical study to investigate the use of udenafil for portal hypertension, an unmet medical need.
Subscribe to our email newsletter
The 200 patient, multi-center, European trial is designed to investigate the safety and efficacy of udenafil, a long acting phosphodiesterase type 5 inhibitor.
Dong Hyun Park, president and CEO of Dong-A PharmTech, said: “Dong-A PharmTech is continuing its development of udenafil for erectile dysfunction in the USA and will develop udenafil for other indications such as benign prostatic hyperplasia and pulmonary hypertension.”